Trial Profile
A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Oct 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Sep 2021 Status changed from active, no longer recruiting to completed.
- 11 Jun 2020 Planned End Date changed from 1 Mar 2021 to 1 Mar 2022.
- 11 Jun 2020 Planned primary completion date changed from 1 Mar 2020 to 1 Mar 2021.